FirstWord: Market Research Reports

Riding the Wearables Trend: Opportunities for Pharma Wearable health technology ... potential? Riding the Wearables Trend: Opportunities for Pharma investigates the potential for wearable devices, ... the expertise of outsiders to successfully adapt to the wearable trend, or create new internal roles and functions? ...

... price harmonisation Will Brexit disrupt EU market access to medicines? Evolving market-access challenges and remedies in Europe ... market access Where market-access policies are heading at national level Key insights Variation and consistency in market-access factors at national level Traditional market-access ...

... nature of FDA not viewed as a hindrance to market access Drugmaker response and market access Key insights RWD could prove helpful in making formulary ... not expected to alter market access The US political climate and market access Key insights Obamacare has had mixed impact on market access, but repeal brings ...

... value-added services? The role of value-added services in cardiometabolic diseases Key insights on the role of value-added services in cardiometabolic diseases The challenge of behavioural change Do VAS influence pricing & reimbursement decisions? Types of value-added services ...

... success look like? And can patient-centric performance be accurately measured or compared? Harnessing Patient Centricity to Drive Profitability takes a pragmatic view across the patient-centric landscape, drawing upon the ...

... set, this ground breaking analysis exposes the pricing, reimbursement and HTA review status of innovative drugs in Australia, Canada, France, Germany and the ... the pricing, reimbursement and HTA status of each product at the national level Profile the therapy areas that are being targeted by innovative drugs ...

... does each of the leading brands compare to its competitors? NPS+ Type 2 Diabetes Mellitus (EU5) gives a unique insight into the overall brand health ... degludec/liraglutide; Novo Nordisk) Explore Important Brand Loyalty Issues NPS+ Type 2 Diabetes Mellitus (EU5) offers valuable insight into brand loyalty from ...

... how does each of the leading brands compare to its competitors? NPS+ Type 2 Diabetes Mellitus (US) gives a unique insight into the overall brand health of ... (liraglutide; Novo Nordisk) Explore Important Brand Loyalty Issues NPS+ Type 2 Diabetes Mellitus (US) offers valuable insight into brand loyalty from the ...

... targeted treatments look set to transform the treatment of moderate to severe atopic dermatitis. As Dupixent (dupilumab; Regeneron/Sanofi) gains traction, older, more ... dupilumab might become a kind of blockbuster drug for the treatment of atopic dermatitis from the data which are available now.” European Key ...

... multiple areas of oncology, and are now approved as treatments for colorectal cancer. But while Keytruda (pembrolizumab; Merck & Co.) and Opdivo (nivolumab; Bristol ... You should move to another target or modify something. I have worked on colorectal cancer for 15 years more or less. I have never seen any Phase ...

... pharma companies renew or upgrade their commercialisation strategies? Key Success Factors in Pricing, Reimbursement and Market Access investigates innovative pharma- ... business now and in the future? What are the key success factors in pricing, reimbursement, and market access contracting? Table of Contents ...

... your brand, and whether market barriers are dragging your market share down, in Market Access Impact: Cancer Pain (EU5). Based on a survey ... PecFent (fentanyl intranasal; Kyowa Kirin) Exploring Market Access Barriers Market Access Impact: Cancer Pain (EU5) explores key issues affecting drug manufacturers. You ...

... ; Celgene) Thalidomide (thalidomide; Celgene) Velcade (bortezomib; Takeda) Exploring Market Access Barriers Market Access Impact: Multiple Myeloma (EU5) explores key issues affecting drug manufacturers. You’ll learn ...

... Subsys (fentanyl sublingual; Insys Therapeutics) Exploring Market Access Barriers Market Access Impact: Cancer Pain (US) explores key issues affecting drug ... Subsys (fentanyl sublingual; Insys Therapeutics) Exploring Market Access Barriers Market Access Impact: Cancer Pain (US) explores key issues affecting drug ...

... and what you can do to win it back, in Market Access Impact: Multiple Myeloma (US). Based on a survey of 100 medical oncologists and ... ; Celgene) Velcade (bortezomib; Takeda) Exploring Market Access Barriers Market Access Impact: Multiple Myeloma (US) explores key issues affecting drug manufacturers. ...

... and primary care physicians across the EU5 (UK, France, Germany, Italy and Spain) the performance of asthma/COPD medical affairs teams still has a way to go ... see more of; and why some are dissatisfied. Use Medical Affairs Reputations: Asthma/COPD 2017 (EU5) to discover how your team can better meet the high ...

... want to see more of; and why some are dissatisfied. Use Medical Affairs Reputations: Asthma/COPD 2017 (US) to discover how your team can better meet the ...

... of haematopoietic stem cells for autologous transplantation in patients with multiple myeloma; Cellectar Biosciences’ announcement of encouraging results from Phase I ... trial investigating CLR 131 in patients with relapsed/refractory multiple myeloma. Business Questions: How does Johnson & Johnson’s and ...

... how does each of the leading brands compare to its competitors? NPS+ CLL (EU5) gives a unique insight into the overall brand health of 6 leading ... ; AbbVie) Zydelig (idelalisib; Gilead) Explore Important Brand Loyalty Issues NPS+ CLL (EU5) offers valuable insight into brand loyalty from the perspective ...

... each of the leading brands compare to its competitors? NPS+ CLL (US) gives a unique insight into the overall brand ... ; Gilead) Explore Important Brand Loyalty Issues NPS+ CLL (US) offers valuable insight into brand loyalty ... the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into ...

... , versus Sutent in patients with previously untreated, advanced or metastatic RCC; Exelixis’ filing for US FDA approval of Cabometyx for the ... combination regimens in patients with previously untreated advanced or metastatic RCC? What other barriers to standard practice will Opdivo/ipilimumab/Cabometyx ...

... have the potential to impact the treatment landscape of rheumatoid arthritis (RA). Topics covered in this update bulletin include expert opinions on; Johnson & Johnson announcing the ...

... needed to foster an environment which incentivises the use of biosimilars. The US biosimilars market is just beginning to evolve towards maturity but ... Global Biologics, Mylan, US Cheryl Schwartz, General Manager, US Biosimilars, Pfizer, US Anonymous expert, with extensive regulatory and medical affairs ...

Will novel therapies transform the treatment of type 2 diabetes? The treatment of type 2 diabetes mellitus has evolved in recent years with introduction of new classes ... to succeed? Learn how KOLs see the type 2 diabetes market evolving in KOL Insight: Type 2 Diabetes. Twelve US and European KOLs provide candid ...

... approval in the US, new oral therapies are set to transform the ulcerative colitis (UC) treatment landscape. While Pfizer’s JAK inhibitor clearly has a head ... such as anti-TNFs and Takeda’s Entyvio (vedolizumab), in KOL Insight: Ulcerative Colitis. Twelve North American and European KOLs provide their insight ...

Adherence – What Do Pharma Really Know The entire industry is talking about patient centricity ... as they are intended to be taken and reap the benefits accordingly? Adherence: What do pharma really know? explores the main issues including physician impact ...

This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) space. Topics ... to recommend the approval of Pfizer’s Mylotarg in previously untreated, de novo AML patients? To what extent is the ALFA-0701 trial considered compelling ...

... to differentiate their marketed and pipeline therapies in KOL Insight: Bladder Cancer. Twelve US and European KOLs provide their candid insights on ... how do KOLs view Cyramza (ramucirumab) as a potential treatment for bladder cancer? What will be critical for commercial success in this indication? Which ...

... events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: Roche announcing results from ...

... to differentiate their pipeline therapies in KOL Insight: Chronic Lymphocytic Leukaemia (CLL). Twelve US and European KOLs provide their candid insights on seven ... oral targeted drugs? How will Imbruvica’s role evolve in treatment of CLL? Following expanded approval of Janssen/AbbVie’s Imbruvica to first-line ...

This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; ... ) which were presented at the 40th European Cystic Fibrosis Society Conference in Seville, Spain in June 2017; and Verona Pharma initiating a Phase II ...

... with solid tumours, including HNSCC, were presented at ASCO 2017; Merck & Co. announced ... that the Phase III KEYNOTE-040 trial of Keytruda in previously treated patients with recurrent or metastatic HNSCC ... potential combination treatment regimens for HNSCC? How do KOLs interpret the ...

... narrow, but significant lead. Get the details in Market Access Impact: NSCLC (EU5). You’ll see how widely prescribed your brand is, ... Pfizer/Merck Group) Zykadia (ceritinib; Novartis) Exploring Market Access Barriers Market Access Impact: NSCLC (EU5) explores key issues affecting drug manufacturers. You’ll ...

... to overtake their closest rivals. Get the details in Market Access Impact: NSCLC (US). You’ll see how widely prescribed your brand is, ... Pfizer/Merck Group) Zykadia (ceritinib; Novartis) Exploring Market Access Barriers Market Access Impact: NSCLC (US) explores key issues affecting drug manufacturers. You’ll ...

... more of; and why some are dissatisfied. Use Medical Affairs Reputations: Chronic Lymphocytic Leukaemia 2017 (EU5) to discover how your team can better meet ... What specifically are they asking for? Insight into Medical Affairs Teams for These CLL Brands Arzerra (ofatumumab; Novartis/Genmab) Gazyvaro (obinutuzumab ...

... down Our latest survey shows that while medical affairs teams for growth hormone brands in the EU5 countries (France, Germany, Italy, Spain, ... doctors, and get a leg up on the competition, in Medical Affairs Reputations: GHD (EU5). Comparing 7 major growth hormone brands from Eli Lilly, Ipsen, Ferring, Merck ...

... want to see more of; and why some are dissatisfied. Use Medical Affairs Reputations: Chronic Lymphocytic Leukaemia 2017 (US) to discover how your team can ... Could addressing these tip the balance? Insight into Medical Affairs Teams for These CLL Brands Arzerra (ofatumumab; Novartis) Gazyva (obinutuzumab; Roche ...

... doctors down Our latest survey shows that while medical affairs teams for growth hormone brands in the EU5 countries (France, Germany, Italy ... with doctors, and get a leg up on the competition, in Medical Affairs Reputations: GHD (EU5). Comparing 7 major growth hormone brands from Eli Lilly, Ipsen, Ferring ...

... the arrival of Array BioPharma’s binimetinib/encorafenib combination to the melanoma treatment landscape? How does Array’s binimetinib/encorafenib compare to Novartis ... give way to Imlygic/Keytruda? What do KOLs think? Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement ...

... ) from the US and Europe on a variety of recent events in the multiple sclerosis (MS) treatment landscape. Topics covered include; Roche reporting that a German ... of Mavenclad (cladribine) for the treatment of relapsing forms of multiple sclerosis (RMS) in patients with high disease activity, and presenting new ...

... shape the treatment landscape of nonalcoholic steatohepatitis (NASH). Topics covered include expert opinions on the ... of acetyl-CoA carboxylase (ACC), in patients with NASH. Business Questions: How do KOLs view the positive ... GS-0976 at EASL 2017, and are they hopeful about the therapy in NASH? Are the experts ...

... for improvement. Find out what they are in FirstView’s NPS+ Haemophilia A 2017 (EU5). You’ll learn how doctors rated your brand, get insight ... and 22nd, 2017. Explore Important Brand Loyalty Issues NPS+ Haemophilia A 2017 (EU5) explores key issues affecting brand loyalty for drug manufacturers ...

... score in FirstView’s NPS+ Haemophilia B 2017 (EU5). Building on the respected net promoter score (NPS), the report compares six major haemophilia drugs, and shows ... and 22nd, 2017. Explore Important Brand Loyalty Issues NPS+ Haemophilia B 2017 (EU5) explores key issues affecting brand loyalty for drug ...

... Spain, Germany, Italy and the UK. NPS+ Rheumatoid Arthritis (EU5) provides clear insight into the results, giving ... . Explore Important Brand Loyalty Issues NPS+ Rheumatoid Arthritis (EU5) gives you clear and independent ... the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into ...

... satisfaction score in FirstView’s NPS+ Haemophilia A 2017 (US). Building on the respected net promoter score (NPS), the report compares nine major haemophilia A drugs, and ... 1st and 22nd, 2017. Explore Important Brand Loyalty Issues NPS+ Haemophilia A 2017 (US) explores key issues affecting brand loyalty for ...

... score in FirstView’s NPS+ Haemophilia B 2017 (US). Building on the respected net promoter score (NPS), the report compares six major haemophilia drugs, and shows ... 1st and 22nd, 2017. Explore Important Brand Loyalty Issues NPS+ Haemophilia B 2017 (US) explores key issues affecting brand loyalty for ...

... You Need to Grow. How does NPS work? NPS measures overall brand satisfaction and loyalty ... , 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5. NPS can range from -100 (everybody is a Detractor) to + ... the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into ...

How will immunotherapy combination regimens impact the NSCLC treatment landscape? The pace of change in NSCLC shows no sign of abating. Developments in immunotherapy ... approvals, could shake up the treatment algorithm for ALK-positive NSCLC, as well as developments in EGFR-, BRAF- and ROS1-positive disease ...

Payer Attitudes to Orphan Drug Funding The explosion of orphan drugs across Europe and the US is pushing healthcare finances towards breaking point according to payers. Requests for orphan drug designation have reached ...

... to alter the RA treatment algorithm? What level of discount do payers demand in order to facilitate market penetration of biosimilar adalimumab? How ... RA? What factors will drive the acceptance of biosimilars by payers? How will payers manage the use of biosimilars in treatment-naïve and treatment-experienced ...